Title |
Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
|
---|---|
Published in |
Patient related outcome measures, November 2017
|
DOI | 10.2147/prom.s117549 |
Pubmed ID | |
Authors |
Adam Ioannou, Irene Tsappa, Sofia Metaxa, Constantinos G Missouris |
Abstract |
Atrial fibrillation is the most common arrhythmia worldwide, and carries a significantly increased risk of thromboembolic stroke. Initially, vitamin K antagonists were used as stroke prophylaxis; but more recently, a group of drugs known as novel oral anticoagulants have been developed. Apixaban belongs to this group of drugs, and is a factor Xa inhibitor that has emerged as a popular pharmacological agent worldwide. In this review, we will provide an overview of the pivotal trials in the development of apixaban, while also critically evaluating the new emerging real-world data, and discussing the effectiveness, safety, economic viability and future prospects of apixaban and how it impacts on patient outcomes in those with non-valvular atrial fibrillation. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 20 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 25% |
Student > Ph. D. Student | 3 | 15% |
Other | 3 | 15% |
Student > Postgraduate | 1 | 5% |
Unknown | 8 | 40% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 4 | 20% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 10% |
Mathematics | 1 | 5% |
Agricultural and Biological Sciences | 1 | 5% |
Nursing and Health Professions | 1 | 5% |
Other | 0 | 0% |
Unknown | 11 | 55% |